Today: 21 May 2026
Browse Category

NASDAQ:AZI 7 November 2025 - 22 December 2025

Autozi Internet Technology (Global) Ltd Stock (NASDAQ: AZI) in Focus on Dec. 22, 2025: CDIB Investment Headlines, Reverse Split Fallout, and What Comes Next

Autozi Internet Technology (Global) Ltd Stock (NASDAQ: AZI) in Focus on Dec. 22, 2025: CDIB Investment Headlines, Reverse Split Fallout, and What Comes Next

Autozi Internet Technology (Global) Ltd (NASDAQ: AZI) surged 64% to close at $2.50 on December 19, with volume over 80 million shares after confirming a $90 million equity investment from CDIB at $3.50 per share. A separate non-binding proposal from CDIB outlines a potential $300 million deal at $5.00 per share. Pre-market trading on December 22 showed AZI near $4 amid continued volatility.
22 December 2025
··
Autozi Internet Technology (AZI) Rockets on $1 Billion Wanshan Deal – All You Need to Know Today (19 November 2025)

Autozi Internet Technology (AZI) Rockets on $1 Billion Wanshan Deal – All You Need to Know Today (19 November 2025)

Autozi Internet Technology shares spiked over 60% pre-market after announcing a $1 billion cross-border sales framework with Wanshan International. Trading volume topped 281 million shares, but AZI later fell back to $0.0759 after hitting $0.19 intraday. The companies plan to build a supply-chain cloud platform targeting $1 billion in overseas sales within three years.
19 November 2025
·
Autozi Internet Technology (AZI) Surges After Hours on Nov. 7, 2025: What’s Driving AZI Today

Autozi Internet Technology (AZI) Surges After Hours on Nov. 7, 2025: What’s Driving AZI Today

Autozi Internet Technology (NASDAQ: AZI) surged about 27.7% in U.S. after-hours trading Friday, closing near $0.13 after ending the regular session around $0.10. No new filings or press releases were issued. Trading was heavy and volatile. Recent catalysts include a September financing reset, interim results showing strong revenue growth but a wider loss, and a Nasdaq compliance deadline.
7 November 2025
·

Stock Market Today

  • Lumentum Stock Analysis: Buy or Hold Amid Rising Demand and AI Growth
    May 20, 2026, 10:40 PM EDT. Lumentum is experiencing soaring demand as it supplies critical technology used by industry giants Nvidia and Intel. Despite this growth, The Motley Fool's Stock Advisor did not include Lumentum in its latest top 10 stock picks. Stock Advisor's selections have historically outperformed the market, with average returns of 990% versus 206% for the S&P 500, highlighting the significance of their recommendations. Investors should weigh Lumentum's current prospects against these insights before making decisions. The company remains a key player in AI-driven tech, but cautious evaluation is advised amid competitive recommendations.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop